Back to Market返回行情

RDY Dr. Reddy's Laboratories Limited

USHealthcare
$13.89-1.63%ClosedMarket Cap: $11.57B

As of 2026-07-09 16:00

Why RDY matters now

Dr. Reddy's Laboratories Limited (RDY) is a US stock in Healthcare. The latest InvestLog snapshot shows $13.89 with -1.63% on the session and $11.57B in market capitalization; recent performance reads 1-month -1.19% and YTD -5.34%.

The latest financial table shown here is Q4 2026, with revenue of $76.33B, net income of $2.24B, and EPS of $2.68. Investors can compare that operating picture with valuation signals such as P/E 17.55 and FCF yield 2.2%.

The latest indexable market news headline is "India's Torrent Pharma recalls select semaglutide pens after Dr. Reddy's notice" from Reuters.

Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes MUNNIRPALLAM MADHU SUNDAR SUBRAMANIAN filing . These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

17.55

PEG

0.04

P/B

2.81

P/S

3.15

EV/EBITDA

14.76

DCF Value

$15.91

FCF Yield

2.2%

Div Yield

0.6%

Margins & Returns

Gross Margin

52.8%

Operating Margin

14.8%

Net Margin

12.8%

ROE

11.8%

ROA

7.4%

ROIC

8.1%

Financials

PeriodRevenueNet IncomeEPS
Q4 2026$76.33B$2.24B$2.68
FY 2026$353.47B$45.09B$53.92
Q3 2026$87.27B$12.10B$14.52
Q2 2026$88.05B$14.37B$17.25

Analyst Ratings

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 0Buy: 2Hold: 2Sell: 1Strong Sell: 0

Trading Activity

Insider Trades

MUNNIRPALLAM MADHU SUNDAR SUBRAMANIANofficer: Global Head of Quality and PV
Sell2026-04-10
Seth Alpnadirector:
Sell2026-04-01
SAPRA DEEPAKofficer: CEO - API and Services
Sell2026-04-01
MANNAM VENKATA NARASIMHAMofficer: Chief Financial Officer
Sell2026-04-01
BHETHANABOTTLA SRINIVASA PHANIMITRAofficer: Chief Information Officer
Sell2026-04-01

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

IN

Exchange

Beta

0.26

Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.